FDA Grants Breakthrough Therapy Designation to GSK5764227 for Refractory Osteosarcoma
GSK has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to GSK5764227 (GSK’227), an antibody-drug conjugate (ADC) targeting B7-H3.
This designation applies to the treatment of adult patients with relapsed or refractory osteosarcoma who have undergone at least two previous lines of therapy.
The Breakthrough Therapy Designation aims to speed up the development and review process for treatments that address serious conditions and demonstrate potential improvements over existing options.
The FDA’s latest decision is supported by findings from the ARTEMIS-002 study, a phase II clinical trial assessing the efficacy and safety of GSK’227 in patients with relapsed or refractory osteosarcoma and other inoperable bone and soft tissue sarcomas.
Osteosarcoma is the most common primary bone cancer, primarily affecting children and young adults. It accounts for 20–40% of all bone cancer cases, with an annual incidence of 3.3 cases per million in the United States.
Despite being rare, it poses significant challenges, especially as 20–30% of patients with localised disease and 80% of those with metastatic osteosarcoma develop relapsed or refractory conditions.
Treatment options remain limited after first-line chemotherapy, with no established standard of care for those experiencing disease progression after two prior therapies.
GSK’227, also known as HS-20093, is an investigational therapy combining a B7-H3-targeting monoclonal antibody with a topoisomerase inhibitor payload.
GSK continues to focus on advancing oncology research, prioritising therapies for haematologic malignancies, gynaecologic cancers, and other solid tumours. This aims to improve survival outcomes through innovations in immuno-oncology and tumour-targeting treatments.
